TrialThe Lancet. Child & adolescent health2024

Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.

Ravi Savarirayan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.